NCT04280224View on ClinicalTrials.gov

NK Cells Treatment for COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 15, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Novel Coronavirus Pneumonia
Interventions
BIOLOGICAL

NK Cells

twice a week of NK cells (0.1-2\*10E7 cells/kg body weight)

Trial Locations (1)

453000

The First Affiliated Hospital of Xinxiang Medical University, Xinxiang

All Listed Sponsors
collaborator

First Affiliated Hospital of Xinjiang Medical University

OTHER

lead

Xinxiang medical university

OTHER

NCT04280224 - NK Cells Treatment for COVID-19 | Biotech Hunter | Biotech Hunter